Abstract. To determine the sensitivity for detection of coagulation factor deficiencies by commercial reagents for canine plasma, 5 commercial activated partial thromboplastin time (APTT) reagents with different types of contact activator and phospholipid of various origin were examined. Thirty canine plasma samples with minor or moderate deficiencies of coagualition factors that influence the APTT were examined. Significant differences were found for the sensitivity of various reagents, but no correlation was found with the type of contact activator. Following the test instructions provided by the manufacturers, the number of APTT results that were prolonged beyond the reference range varied between 20 and 30 (sensitivity ϭ 0.67-1.00); the number of corresponding results using a standardized test protocol varied between 19 and 28 (sensitivity: 0.63-0.93). The most sensitive reagent contained kaolin as a contact activator and a human placental thromboplastin. The results of this study indicate that the APTT test optimized for human plasma is also a sensitive screening test of the intrinsic system of canine plasma, provided that a suitable reagent is used.
Although modern coagulation diagnostics is becoming increasingly complex, screening tests such as the activated partial thromboplastin time (APTT) 13 are still important for basic examination. 4 Therefore, the APTT is a commonly used screening test for the endogenous coagulation system of dogs and humans. Usually, measurements for dogs are performed uncritically, following test instructions, with commercial reagents that have been optimized for human plasma. 4 Numerous articles are available in which the sensitivity of different APTT reagents to detect coagulation deficiencies as an important quality criterion is documented in detail for human plasma. 2, 3, [5] [6] [7] [8] [9] 11, 12 The sensitivity of the reagents tested was found to differ significantly, which was largely attributed to the type of contact activator. 2, 3, 5, [7] [8] [9] 11, 12 Because activity of several coagulation factors of the intrinsic system of canine plasma differs considerably from the system of humans, 15 the results of these studies based on human plasma cannot easily be transferred to canine plasma. Apart from factor VIII:C deficiencies, 10 up to now, no systematic investigations have been conducted about the sensitivity of the APTT for detection of coagulation factor deficiencies for dogs. Therefore, the intention of the present study was to determine the sensitivity of different commercially available APTT reagents to detect minor or moderate deficiencies of coagulation factors of the intrinsic and common pathways of the coagulation system.
Materials and methods
Study design. Based on 52 samples of healthy dogs corresponding reference values were established for the APTT measured with 5 different reagents and the coagulation factors detected by the APTT (II, V, X, VIII:C, IX, XI, XII, prekallikrein, and high molecular weight kininogen [HMWK] ). In addition, the APTT was determined with these 5 reagents for 30 samples with minor or moderate deficiencies of at least 1 of the cited coagulation factors. All the factors mentioned above were also measured in the patient plasmas. The APTT was determined according to the manufacturers' instructions and according to a standardized protocol to exclude differences that result from irregular test procedures. The sensitivity of the reagents was assessed based on the number of samples with a coagulation factor deficiency that show an abnormal APTT.
Sample material. The origins of the 30 plasma samples with coagulation factor deficiencies are given in Table 1 . Samples with abnormal thrombin time were excluded from the study. For 17 samples the lowest individual coagulation factor activity was Ͻ50% (samples 14-30); for the remaining 13 samples the lowest activity was between 50% and the lower limit of the reference range (samples 1-13). The 52 reference samples were collected from clinically healthy dogs of both sexes and various breeds. For all these animals the leukocyte count, hematocrit, concentration of albumin, total protein, creatinine, and total bilirubin, as well as the activity of alanine amino transferase were within their respective reference range.
Collection of sample material. The blood was taken from the cephalic or saphenous vein congested only slightly with sterile diposable cannulas (1.1 ϫ 30 mm). Graduated 10-ml plastic tubes prefilled with 1 ml of 0.11 mol/liter sodium citrate solution a were filled with blood to the 10-ml mark. Immediately afterwards, the plastic tubes were moved care- fully to assure a complete mixture of the blood and anticoagulant. Platelet-poor citrated plasma (PPP) was obtained by centrifugating for 20 min at 2000 ϫ g and at 4 C. The plasma was divided into several aliquots and kept deep frozen at Ϫ70 C until it was analyzed. Activated partial thromboplastin time. Like the thrombin time, the APTT was performed with a semiautomatic crochet coagulometer. b Only 1 defined batch of each of the 5 different commercial reagents was used in this study ( Table 2 ).
The APTT reagents 1 and 2 were reconstituted according to the manufacturers' test instructions, that is, the lyophilized phospholipid preparation was dissolved in 2 ml of the kaolin solution. The other reagents were supplied ready for use. Considering the special features of the individual reagents given by the manufacturer (Table 2) , the APTT was determined according to the following test instruction: 100 l of PPP (in part prewarmed for 1 min at 37 C), 100 l of APTT reagent (in part prewarmed to 37 C), incubation for 2 or 3 min at 37 C, addition of 100 l of CaCl 2 solution (37 C; 20 c or 25 d mmol/liter and simultaneous start of the stop watch). As stated above, on the one hand the present study followed the APTT reagent manufacturers' test instructions. On the other hand, measurements were performed according to a standardized test instruction that eliminates factors other than the reagent composition that may influence measurement results, such as preincubation of the samples and reagent at 37 C, incubation time for the mixture of PPP and reagent, and CaCl 2 concentration. The standardized test was carried out without prewarming the reagent or plasma, with an incubation time of 3 min and 25 mmol/liter CaCl 2 solution. This corresponded to the test instructions given by the manufacturer for reagent 2. Therefore, another measurement with an incubation time of 2 min was performed for this reagent.
Thrombin time. The thrombin time was measured with a commercial test reagent e (thrombin activity in the working solution: 3 IU/ml) following the test instructions of the manufacturer.
Activity of individual coagulation factors. The activity of individual coagulation factors was measured with commercial human deficient plasma of different manufacturers. f A 1:40 predilution of the sample plasma was prepared with buffer solution. g To determine the coagulation factors II, V, and X, 50 l of prediluted sample and 50 l of deficient plasma were incubated for 1 min at 37 C. 200 l of calcium thromboplastin h tempered at 37 C were added at the time the stopwatch was started to measure the coagulation time. The coagulation factors VIII:C, IX, XI, and XII as well as prekallikrein and HMWK were determined according to the following test instruction: after adding 100 l of the APTT reagent to 50 l of prediluted PPP, and 50 l of deficient plasma, the mixture was incubated for exactly 3 min at 37 C. The stopwatch was started when 100 l of 25 mmol/liter CaCl 2 solution (37 C) were added.
The coagulation activity (%) was calculated from the reference curves. These were prepared for each reagent batch using different dilutions of a canine pool plasma (n Ͼ 100 healthy dogs, coagulation activity ϭ 100%) as standards.
Statistical methods. Reference ranges were defined on the basis of 2.5% and 97.5% quantils. A comparison of the positive test results of different reagents was performed according to Fisher's exact test.
Results
The results of 30 canine plasmas with a slightly or moderately reduced activity of at least 1 of the coagulation factors that influence the reaction course of the APTT test system show that the sensitivity of the APTT in dogs largely depends on the reagent (Table  1 ). In addition, it was demonstrated that with a suitable reagent optimized for human plasma the APTT also represents a sensitive screening test of the intrinsic system for canine plasma. Extended APTT was found for 20-30 of the 30 samples with coagulation factor deficiencies (sensitivity ϭ 0.67-1.00) if measured according to the manufacturers' instructions, and for 19-28 of the samples (sensitivity: 0.63-0.93) if measured according to the standardized test procedure. In both cases, the highest sensitivity was assigned to reagent 1, followed by the reagents 3 and 4. If measured according to the uniform test procedure the number of positive results with reagent 1 (n ϭ 28) was significantly higher than with less sensitive reagents. For example, this was true for reagent 2 (n ϭ 21, P ϭ 0.0195), which, like reagent 1, contained kaolin as a contact activator, as well as for reagent 5 (n ϭ 19, P ϭ 0.0048). The low sensitivity of reagent 5 could also be proven if statistically compared to reagent 3 (P ϭ 0.0369).
With regard to the 17 samples with at least an individual factor activity Ͻ50%, the APTT measured with reagents 3 and 4 for all samples, as with reagent 1, was above the reference range, with 1 exception (sample 10, reagent 3, test instructions according to the manufacturer; Table 1 ). For reagents 2 and 5 only 14 or 13 samples showed a prolongation above the reference range. For the 4 samples with at least 1 factor reduced to values Ͻ30% (samples 27-30), all measurements performed had an abnormal APTT regardless of the APTT reagent used. A comparison of the measurements performed according to the standardized test and according to the manufacturers' instructions showed that none of the reagents examined had a significant difference with respect to the number of abnormal results (P Ͼ 0.2). As a result, no significant dependence of sensitivity on incubation time could be proven for the APTTs of reagent 1 (P ϭ 0.2458) and reagent 2 (P ϭ 0.6106), which were measured with an incubation time of 2 and 3 minutes.
Discussion
The intention of the present study was to examine the sensitivity of different APTT reagents for detecting factor deficiencies in canine plasma. In recent years, the demands for clotting factor sensitivity of the APTT have increased in human medicine. For a long time, the APTT has been demanded to be able to detect coagulation factor deficiencies with residual activities of 30% or less to be a useful test. 11, 13 However, studies have shown that a decrease in human coagulation factor activity to values between 30 and 50% may also be associated with an increased bleeding risk, mainly intraoperatively. 7 As a consequence, especially for preoperative screening, an individual factor activity below 50% ideally must be detected. 2, 7 The present study shows that the more sensitive of the reagents investigated (reagents 1, 3, and 4) also fulfill these higher standards for canine plasma. Moreover, with the most sensitive reagent 1 all samples (n ϭ 13) with a residual coagulation factor activity of at least 50% were detected if measurements were performed according to the manufacturer's instruction. This indicates a nearly ideal screening test, which probably must be assigned to the optimum test conditions of the present study, especially the batch-specific reference ranges.
The sensitivity testing used in this study, that is, measurement of patient plasmas in contrast to other types of sensitivity testings such as mixture of pool plasma with single factor deficient plasma, considered effects that in some cases may disguise an APTT extension. For example, APTT prolongation might be compensated in part by the presence of activated clotting factors in test plasmas, low levels of inhibitors, or high concentrations of clotting factors other than the deficient one. 3 On the other hand, by disregarding samples with prolonged thrombin time, it was excluded that disorders of fibrin generation (severe hypofibrinogenaemia or increased concentration of fibrin (ogen) degradation products) extended the APTT independent of a single factor deficiency and, thereby, misled to an incorrect high single factor sensitivity.
The coagulation factor sensitivity of the APTT obtained in this study for canine plasma must be assessed to be even more valuable because investigations of the sensitivity of different APTT reagents with human plasma have shown that clotting factor activities decreased to values between 30 and 50% are reliably detected only by a few selected reagents. 2, 5, 7, 11 Even single factor deficiencies Ͻ30% cannot be detected in every case. 5, 7, 8 In this context, reference is made to a study based on 19 human samples with deficiencies of factors VIII, IX, XI, XII, or II, with remaining factor activities between 2.5 and 52%, in which 0-8 falsenormal results were found for 5 different commercial reagents examined. 5 The coagulation factor activities of the samples not detected varied between 13 and 50%. Considerable variation with respect to the sensitivities of different reagents have also been shown in other studies on human plasma. 7, 8 Because sensitivities of APTT reagents that contained ellagic acid as a contact activator as well as those with kaolin varied considerably, the results of the present study do not confirm other studies on human material that assign a low sensitivity to reagents with ellagic acid. 5, 7 The results of this study support the results found in another study on human plasma. 9 Previous studies have also demostrated that the sensitivity of the APTT test system is related to the type of phospholipid material in the reagent. 13, 14 The results of measurement of reagents 1 and 2 did not provide distinct evidence that the sensitivity of the APTT is influenced by incubation time. Such a relationship has been documented for human plasma. 1 In conclusion, the results of this study indicate that the APTT measured using commercial reagents intended for human use is a suitable screening test for
